kroller
neapharma s.rl. - ketorolac - ketorolac
mekinist
novartis europharm limited - trametinib - melanoma - agenti antineoplastici - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 e 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non a piccole cellule del polmone (nsclc)trametinib in combinazione con dabrafenib è indicato per il trattamento di pazienti adulti con avanzato non a piccole cellule cancro ai polmoni con una braf v600 mutazione.
febrifugam
fatro s.p.a. - paracetamolo - paracetamolo - 200 mg/ml - paracetamol
harmonet 21cpr 0,075mg 0,02mg
medifarm srl - etinilestradiolo/gestodene - compresse rivestite - "0,075 mg + 0,02 mg compresse rivestite" 21 compresse - gestodene ed estrogeno - contraccettivi ormonali sistemici
carbamazepina eg
eg s.p.a. - carbamazepina - carbamazepina
harmonet
medifarm s.r.l. - gestodene ed estrogeno - gestodene ed estrogeno
exparel liposomal
pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.
tafinlar
novartis europharm limited - dabrafenib mesilate - melanoma - agenti antineoplastici - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 e 5. il trattamento adiuvante di melanomadabrafenib in combinazione con trametinib è indicato per il trattamento adiuvante di pazienti adulti con melanoma in stadio iii con un braf v600 mutazione, a seguito di una completa resezione. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
mabthera subkutan 1400 mg/11.7 ml soluzione per iniezione sottocutanea
roche pharma (schweiz) ag - rituximabum - soluzione per iniezione sottocutanea - rituximabum 1400 mg, hyaluronidasum humanum adnr, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 11.7 ml. - non-hodgkin lymphome - biotechnologika
mabthera subkutan 1600 mg/13.4 ml soluzione per iniezione sottocutanea
roche pharma (schweiz) ag - rituximabum - soluzione per iniezione sottocutanea - rituximabum 1600 mg, hyaluronidasum humanum adnr, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 13.4 ml. - non-hodgkin lymphome - biotechnologika